Evidence map›Paper›PMID 41772041›Full record

ArticleScientific reports2026

Quantitative analysis of myeloid cell patterns and immunosuppressive enzyme (IDO, ARG1) expression in colorectal cancer pulmonary metastases and corresponding primary tumours.

Topias Karjula, Hanna Elomaa, Sara A Väyrynen, Vesa-Matti Pohjanen, Maarit Ahtiainen, Jan Böhm, Jukka-Pekka Mecklin, Erkki-Ville Wirta, Toni T Seppälä, Eero Sihvo and 3 more

Abstract read
In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Topias Karjula *Translational Medicine Research Unit, Medical Research Center Oulu, Oulu University Hospital and University of Oulu, Oulu, Finland. topias.karjula@oulu.fi.ORCID http://orcid.org/0000-0002-2342-6034
Hanna Elomaa *Department of Education and Research, Hospital Nova of Central Finland, Well Being Services County of Central Finland, Jyväskylä, 40620, Finland.
Sara A VäyrynenDepartment of Internal Medicine, Oulu University Hospital, Oulu, Finland.
Vesa-Matti PohjanenTranslational Medicine Research Unit, Medical Research Center Oulu, Oulu University Hospital and University of Oulu, Oulu, Finland.
Maarit AhtiainenCentral-Finland Biobank, Well Being Services County of Central Finland, Jyväskylä, 40620, Finland.
Jan BöhmDepartment of Pathology, Hospital Nova of Central Finland, Well Being Services County of Central Finland, Jyväskylä, 40620, Finland.
Jukka-Pekka MecklinDepartment of Education and Research, Hospital Nova of Central Finland, Well Being Services County of Central Finland, Jyväskylä, 40620, Finland.
Erkki-Ville WirtaFaculty of Medicine and Health Technology, Tampere University and TAYS Cancer Center, Tampere University Hospital, Tampere, 33520, Finland.
Toni T SeppäläDepartment of Gastrointestinal Surgery, Helsinki University Central Hospital, University of Helsinki, Helsinki, 00290, Finland.
Eero SihvoCentral Hospital of Central Finland, Jyväskylä, 40014, Finland.
Fredrik YannopoulosTranslational Medicine Research Unit, Medical Research Center Oulu, Oulu University Hospital and University of Oulu, Oulu, Finland.
Olli HelminenTranslational Medicine Research Unit, Medical Research Center Oulu, Oulu University Hospital and University of Oulu, Oulu, Finland.
Juha P VäyrynenTranslational Medicine Research Unit, Medical Research Center Oulu, Oulu University Hospital and University of Oulu, Oulu, Finland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Indoleamine-2,3-dioxygenase (IDO) and arginase1 (ARG1) are immunosuppressive enzymes frequently overexpressed in cancer, with higher expression in colorectal cancer primary tumours paradoxically linked to favourable survival. Their significance in metastases remains unexplored. Employing multiplexed immunohistochemistry and supervised machine learning-based digital image analysis, we analysed the IDO and ARG1 expression in monocytic cells, granulocytes, mast-cells and tumour cells in 91 resected pulmonary metastases from 53 corresponding primary tumours. We also evaluated the spatial distribution of IDO+ and ARG1+ cells relative to tumour cells and compared these patterns between metastases and primary tumours. In metastases, higher IDO+ monocytic cell densities in the tumour centre were associated with favourable survival (adjusted HR 0.17, 95%CI 0.05–0.59, p = 0.005), while higher IDO– monocytic cell densities in the invasive margins were associated with worse survival (adjusted HR 4.19, 95%CI 1.45–12.05, p = 0.008). Moreover, higher densities of IDO+HLA-DR− immature monocytic cells and IDO+FCGR3+ monocytic cells in the invasive margin were also associated with poor survival, after adjusting for T-cell densities (adjusted HRs 26.4, 95%CI 4.95 − 140.42, p < 0.001 and 3.91 95%CI 0.97 − 15.76, p = 0.056, respectively). These findings provide detailed insights into the immunosuppressive myeloid cell landscape in colorectal cancer pulmonary metastases, highlighting key differences from primary tumours and potential implications for therapy development.

Indexed as

ArginaseColorectal NeoplasmsIndoleamine-Pyrrole 2,3,-DioxygenaseLung NeoplasmsMyeloid CellsAgedFemaleHumansMaleMiddle AgedPrognosisARG1 protein, humanArginaseIndoleamine-Pyrrole 2,3,-DioxygenaseARG1Cancer immunologyColorectal cancerIDOMyeloid cellsPulmonary metastases

Identifiers

PMID41772041
PMCPMC13066423

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.